The OPTION trial showed equivalence between Watchman FLX and oral anticoagulation in preventing stroke, systemic embolism, and all-cause death post-ablation. Subgroup analyses revealed consistent ...
Boston Scientific (NYSE:BSX) today shared new clinical findings supporting its wide-ranging electrophysiology (EP) portfolio.
First phase of ADVANTAGE AF clinical trial achieves safety and effectiveness endpoints for treatment of drug-resistant, symptomatic, persistent atrial fibrillation with the FARAPULSE™ Pulsed Field ...
Please provide your email address to receive an email when new articles are posted on . OPTION is a head-to-head trial of left atrial appendage closure with Watchman FLX vs. anticoagulation after ...
MARLBOROUGH, Mass., May 22, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has initiated the OPTION trial to compare safety and effectiveness of the next-generation WATCHMAN FLX™ left ...
Boston Scientific (NYSE:BSX) released new clinical trial results for its FARAPULSE PFA Platform and WATCHMAN LAAC at Heart ...
The heart rhythm disorder called atrial fibrillation (AFib) can affect people of any age, but is most common in older adults. It may start with a rapid heartbeat, a fluttering feeling in a person’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results